INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/05/2025
Back to search
Official data from USPTO
ELASTATHERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ELASTATHERAPY
ST13
US500000079205352Class
3, 5
Filing
79205352
Registration
5398619
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
09/10/2025
Trademark type
Word
Nice classes
3, 5
Filing date
01/18/2017
Registration date
02/13/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/30/2024
Last transaction
09/10/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
77
Owner location
IE
Examiner
FRENCH, CURTIS
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Allergan Pharmaceuticals International Limited
Elastagen Pty Ltd
Representatives
Louis K. Ebling Thompson Hine LLP
Technical classification
Nice Classes
Class 3Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Cosmetics in the form of gelsfoamscreamslotionsmilks and powders; cosmetic preparations; skin moisturizers
Class 5
Pharmaceutical preparations and compositions for the treatment of acquired and congenital skin conditions and acquired and congenital skin diseases; biochemical and biological substances for medical useforms of protein and polysaccharide preparations for the treatment of acquired and congenital skin conditions and acquired and congenital skin diseases; drug delivery preparations for medical useforms of protein and polysaccharide preparations used for the controlled release of pharmaceuticals; medical preparationsmedicated skin care preparations
Publications
History of USPTO decisions and trademark events.
34 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/16/2025
INPC
INVALIDATION PROCESSED
08/16/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
04/30/2025
CHLD
CHANGE OF OWNER RECEIVED FROM IB
09/30/2024
C71T
CANCELLED SECTION 71
08/30/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/13/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/15/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/16/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/29/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/21/2018
FIMP
FINAL DISPOSITION PROCESSED
05/21/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/13/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
02/13/2018
GPNX
NOTIFICATION PROCESSED BY IB
12/29/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/28/2017
PUBO
PUBLISHED FOR OPPOSITION
11/28/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/22/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/22/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/22/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/18/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/17/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/17/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/17/2017
RFNT
REFUSAL PROCESSED BY IB
05/20/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/24/2017
RFRR
REFUSAL PROCESSED BY MPU
04/24/2017
MAFR
APPLICATION FILING RECEIPT MAILED
04/21/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/20/2017
CNRT
NON-FINAL ACTION WRITTEN
04/19/2017
DOCK
ASSIGNED TO EXAMINER
04/17/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/17/2017
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
04/13/2017
Continuous trademark protection
Get notified about every new filing that threatens ELASTATHERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.